-
Mashup Score: 43Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma - 2 month(s) ago
In the phase III HIMALAYA study (NCT03298451) in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly improved overall survival (OS) versus sorafenib; durvalumab monotherapy was noninferior to sorafenib for OS. Results reported herein are from a 4-year updated OS analysis of HIMALAYA.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4ثانوية المربية ثريا فارس ابو علفا الرسمية - 2 month(s) ago
During their English session,Grade 10 students have decided to go green and add a vibrant atmosphere to the school. Everyone of them has a green thumb.
Source: www.facebook.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8
Sorafenib blocks NS5A-recruited c-Raf-mediated hepatitis C virus (HCV) replication and gene expression. Release of Raf-1-Ask-1 dimer and inhibition of Raf-1 via sorafenib putatively differ in the presence or absence of doxorubicin. CALGB 80802 (Alliance) randomized phase III trial of doxorubicin plu …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17
In Reply We thank Abou-Alfa and Sangro for their comments on our review of systemic therapies for hepatocellular carcinoma (HCC).1 They raise valid concerns that we would like to address.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 12Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma - 5 month(s) ago
The liver tumor immune microenvironment has been thought to possess a critical role in the development and progression of hepatocellular carcinoma (HCC). Despite the approval of immune checkpoint inhibitors (ICIs), such as programmed cell death receptor 1 (PD-1)/programmed cell death ligand 1 (PD-L1) and cytotoxic T lymphocyte associated protein 4 (CTLA-4) inhibitors, for several types of cancers, including HCC, liver metastases have shown evidence of resistance or poor response to immunotherapies. Radiation therapy (RT) has displayed evidence of immunosuppressive effects through the upregulation of immune checkpoint molecules post-treatment. However, it was revealed that the limitations of ICIs can be overcome through the use of RT, as it can reshape the liver immune microenvironment. Moreover, ICIs are able to overcome the RT-induced inhibitory signals, effectively restoring anti-tumor activity. Owing to the synergetic effect believed to arise from the combination of ICIs with RT, se
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17Therapeutic developments in pancreatic cancer - Nature Reviews Gastroenterology & Hepatology - 6 month(s) ago
The incidence of pancreatic ductal adenocarcinoma (PDAC) is rising. In this Review, Hu and O’Reilly summarize the latest advances and clinical trials for the treatment of PDAC, including biomarkers, targeted therapies and immunotherapy as well as novel clinical trial designs. They also discuss emerging therapeutic options for this disease.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16Africa Guidelines for Hepatocellular Carcinoma Buildup Process - 6 month(s) ago
PURPOSE Hepatocellular carcinoma (HCC), the fourth most common cancer in Africa, has a dismal overall survival of only 3 months like in sub-Saharan Africa. This is affected by the low gross domestic product and human development index, absence of coherent guidelines, and other factors. METHODS An open forum for HCC-experienced health care workers from Africa and the rest of the world was held in October 2021. Participants completed a survey to help assess the real-life access to screening, diagnoses, and treatment in the North and Southern Africa (NS), East and West Africa (EW), Central Africa (C), and the rest of the world. RESULTS Of 461 participants from all relevant subspecialties, 372 were from Africa. Most African participants provided hepatitis B vaccination and treatment for hepatitis B and C. More than half of the participants use serum alpha-fetoprotein and ultrasound for surveillance. Only 20% reported using image-guided diagnostic liver biopsy. The Barcelona Clinic Liver Ca
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8
Abstract. Introduction: Intratumoral administration of pexa-vec (pexastimogene devacirepvec), an oncolytic and immunotherapeutic vaccinia virus, given to patients with hepatocellular carcinoma (HCC), is associated with both local and distant tumor responses. We hypothesized subsequent treatment with sorafenib could demonstrate superior efficacy. Methods: This random phase III open-label study evaluated the sequential treatment with pexa-vec followed by sorafenib compared to sorafenib in patients with advanced HCC and no prior systemic treatment. The primary endpoint is overall survival (OS). Key secondary endpoints included time to progression (TTP), progression-free survival, overall response rate (ORR), and disease control rate (DCR). Safety was assessed in all patients who received ≥1 dose of study treatment. Results: The study was conducted at 142 sites in 16 countries. From December 30, 2015, to the interim analysis on August 2, 2019, 459 patients were randomly assigned (pexa-vec
Source: karger.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17Therapeutic developments in pancreatic cancer - Nature Reviews Gastroenterology & Hepatology - 6 month(s) ago
The incidence of pancreatic ductal adenocarcinoma (PDAC) is rising. In this Review, Hu and O’Reilly summarize the latest advances and clinical trials for the treatment of PDAC, including biomarkers, targeted therapies and immunotherapy as well as novel clinical trial designs. They also discuss emerging therapeutic options for this disease.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8
I just registered for an upcoming Answers in CME In-Person & Virtual Satellite Symposium—Nov 12 on #HCC in Boston. Want to join me? #HCC #Gastro #Oncology #Hepatology #MedEd #CME #TLM23
Source: d.answersincme.comCategories: General Medicine News, Oncologists1Tweet
Years, not months. @MSKCancerCenter @MSK_DeptOfMed @GABOUALFA present collaborative efforts of Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable #HCC in @Annals_Oncology https://t.co/PoC5X8HoE1